Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | S100B | P04271 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060663 | 0.80 | NOS3 (0.37) | ALDH1A1NOS3NOS2USP7S100B | |
| SCHEMBL11700766 | 0.80 | FEN1 (0.32) | NOS3NOS2USP7 | |
| SCHEMBL1170745 | 0.78 | SKP2 (0.41) | — | |
| SCHEMBL6652156 | 0.77 | ALDH1A1 (0.34) | ALDH1A1NOS3NOS2USP7S100B | |
| SCHEMBL982159 | 0.74 | NOS2 (0.47) | ALDH1A1NOS3NOS2S100BCD44 | |
| SCHEMBL571458 | 0.74 | POLB (0.40) | ALDH1A1NOS3NOS2CD44 | |
| SCHEMBL24620497 | 0.73 | NOS3 (0.35) | ALDH1A1NOS3NOS2USP7S100B | |
| SCHEMBL8370064 | 0.73 | TAAR1 (0.41) | ALDH1A1USP7CD44 | |
| SCHEMBL3678294 | 0.73 | TAAR1 (0.32) | ALDH1A1 | |
| SCHEMBL3672155 | 0.73 | NOS3 (0.32) | ALDH1A1NOS3NOS2S100BCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-9636345-B2 | Benzimidazole derivatives useful TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| EP-3131880-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015159233-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-10-22 | — | — | WO | disclosed |
| US-20150150882-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-04 | — | — | US | disclosed |
| US-8981113-B2 | Benzimidazole derivatives useful as TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-17 | — | — | US | disclosed |
| US-20130245085-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | disclosed |
| EP-2440295-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-24 | — | — | EP | disclosed |
| EP-2440294-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-24 | — | — | EP | disclosed |
| EP-2440294-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2440295-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110003801-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003800-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010144680-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144679-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-16 | — | — | WO | disclosed |
| EP-1426392-B1 | COMPOSITION FOR OPTICAL MATERIAL | MITSUBISHI GAS CHEMICAL CO (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-6960640-B2 | Composition for optical material | MITSUBISHI GAS CHEMICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040147708-A1 | Composition for optical material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1426392-A1 | COMPOSITION FOR OPTICAL MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003800-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 1798/4885NOS3 2710/4885NOS2 3392/4885 |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ALDH1A1 1250/4885NOS3 2569/4885NOS2 3027/4885 |
| US-20130245085-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 1798/4885NOS3 2710/4885NOS2 3392/4885 |
| US-20150150882-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 2178/4885NOS3 2722/4885NOS2 3319/4885 |
| US-20110003801-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | ALDH1A1 1798/4885NOS3 2710/4885NOS2 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.